article thumbnail

CIOs look beyond ‘Big 3’ cloud providers for AI innovation

CIO Business Intelligence

Having previously run its AI workloads on premises, the clinical-stage biotechnology company chose Vultr Cloud GPU, a GPU-as-a-service that Athos runs on Dells Nvidia-powered HGX H100 PowerEdge servers to train its homegrown AI models and build its AI-powered precision medicine platform aimed at solving auto-immune and cancerous diseases.

Cloud 323
article thumbnail

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

GeekWire

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. While Sana says its approach is applicable to a number of diseases, some of its most advance research is being done around cancer. And like many biotechnology companies it is losing money. stake in Sana.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Jeff Bezos-backed startup Nautilus Biotechnology set to go public via SPAC at $900M valuation

GeekWire

Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo).

article thumbnail

Deep tech disruption: How advanced technologies are transforming businesses

CIO Business Intelligence

Biotechnology and synthetic biology: The swift development of mRNA vaccines in 2020 illustrated biotechs unprecedented speed in delivering transformative products. Attempting advanced applications without digitizing foundational processes first leads to disappointments, too. Some companies just dont know where to begin.

Industry 295
article thumbnail

Sana Biotechnology boosts IPO range, looks to raise $517 million

GeekWire

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).

article thumbnail

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

GeekWire

Sana Biotechnology has a new $50 million tool in its toolbox. SANA intends to file its first investigational new drug application incorporating the new gene editing platform as early as next year, said Harr. The application with the U.S. Sana CEO and president Steve Harr. Sana Photo).

article thumbnail

Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies

GeekWire

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. Adaptive Biotechnologies , Absci , and Zymeworks also announced layoffs this year. Sana expects to file its first investigational new drug application (IND) this year with the U.S.